This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spectrum Pharmaceuticals Reports Financial Results For Second Quarter 2013

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period ended June 30, 2013.

“We are excited about launching our recently acquired FDA approved anti-cancer product Marqibo®, in the fourth quarter through our existing sales force,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “We also have additional three drugs in late stage development that could be launched in the next 18 to 24 months. The infrastructure we have built over the recent years is the foundation from which we will be able to launch a number of our drugs in the near future. We believe we are in a prime position to fuel Spectrum’s future growth, while we continue to mitigate risk and diversify our products in development and revenue stream.”

Three-Month Period Ended June 30, 2013 (All numbers are approximate)

GAAP Results

Consolidated revenues of $33.2 million was comprised of product net sales of $32.2 million and $1.0 million from licensing fees. This represents a 51.6% decrease from the $68.7 million in consolidated revenue, including product net sales of $65.6 million, recorded in the three-month period ended June 30, 2012.

Product revenues in second quarter included: FUSILEV® (levoleucovorin) net sales of $12.9 million, FOLOTYN® (pralatrexate injection) net sales of $12.6 million and ZEVALIN® (ibritumomab tiuxetan) net sales of $6.8 million.

The Company recorded net loss of $10.2 million, or ($0.17) per basic and diluted share in the three-month period ended June 30, 2013, compared to a net income of $18.1 million, or $0.31 per basic and $0.29 per diluted share in the comparable period in 2012. Total research and development expenses were $10.5 million in the quarter, as compared to $9.6 million in the same period in 2012. Selling, general and administrative expenses were $22.6 million in the quarter, compared to $23.3 million in the same period in 2012.

1 of 12

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs